YCT529 is an experimental non-hormonal male contraceptive developed by YourChoice Therapeutics. It functions as a selective antagonist of the retinoic acid receptor alpha (RAR-α), a nuclear receptor involved in vitamin A signaling. By inhibiting RAR-α, YCT529 disrupts spermatogenesis, leading to temporary infertility. YCT529 targets RAR-α, which plays a crucial role in the vitamin A signaling pathway essential for sperm production. By selectively inhibiting RAR-α, the drug impedes the development and maturation of sperm cells without affecting other physiological processes governed by vitamin
YCT529 is an experimental non-hormonal male contraceptive developed by YourChoice Therapeutics. It functions as a selective antagonist of the retinoic acid receptor alpha (RAR-α), a nuclear receptor involved in vitamin A signaling. By inhibiting RAR-α, YCT529 disrupts spermatogenesis, leading to temporary infertility. YCT529 targets RAR-α, which plays a crucial role in the vitamin A signaling pathway essential for sperm production. By selectively inhibiting RAR-α, the drug impedes the development and maturation of sperm cells without affecting other physiological processes governed by vitamin A.
== Preclinical studies == In preclinical trials involving male mice, YCT529 demonstrated a 99% efficacy rate in preventing pregnancy. The contraceptive effect was fully reversible, with fertility restored within four to six weeks after discontinuation. No significant side effects were observed during these studies. Similar outcomes were reported in studies with non-human primates, where sperm counts decreased significantly after two weeks of dosing, and normal fertility resumed post-treatment.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).